Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)Biliary Tract Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, biliary tract disorder, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, pancreatic ductal adenocarcinoma, rectal disorderRecruitingPhase 1 / Phase 22026-09-28NCT05482893

2 results · Page 1 of 1

Swipe the table sideways for more columns.

OrganizationsLinked trials
Merck Sharp & Dohme LLC650
Phanes Therapeutics3

11 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
City of Hope (City of Hope National Medical Center, City of Hope Medical Center)DuarteUnited States15
Dana-Farber Cancer Institute (DFCI)BostonUnited States4
Duke Cancer CenterDurhamUnited States44
MD Anderson Cancer Center, GI Medical Oncology DeptHoustonUnited States1
NEXT OncologyFairfaxUnited States31
Norton Cancer InstituteLouisvilleUnited States26
Sarah Cannon Research Institute (SCRI)DenverUnited States3
University of IowaIowa CityUnited States284
University of Pittsburgh Medical Center (UPMC)PittsburghUnited States4
University of Wisconsin Carbone Cancer Center - University HospitalMadisonUnited States249
Usc Norris Comprehensive Cancer CenterLos AngelesUnited States67